0 CHECKOUT

Tetanus - Pipeline Review, H2 2015

  • ID: 3448666
  • September 2015
  • 89 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Biological E. Limited
  • GlaxoSmithKline Plc
  • Green Cross Corporation
  • LG Life Sciences, Ltd.
  • Panacea Biotec Limited
  • Prometheon Pharma, LLC
  • MORE

Tetanus - Pipeline Review, H2 2015

Summary

The report ‘Tetanus - Pipeline Review, H2 2015’, provides an overview of the Tetanus’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Tetanus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tetanus and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Biological E. Limited
  • GlaxoSmithKline Plc
  • Green Cross Corporation
  • LG Life Sciences, Ltd.
  • Panacea Biotec Limited
  • Prometheon Pharma, LLC
  • MORE

List of Tables

List of Figures

Introduction

REPORT COVERAGE

Tetanus Overview

Therapeutics Development

Pipeline Products for Tetanus - Overview

Pipeline Products for Tetanus - Comparative Analysis

Tetanus - Therapeutics under Development by Companies

Tetanus - Therapeutics under Investigation by Universities/Institutes

Tetanus - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Tetanus - Products under Development by Companies

Tetanus - Products under Investigation by Universities/Institutes

Tetanus - Companies Involved in Therapeutics Development

Beijing Minhai Biotechnology Co., Ltd

Bharat Biotech International Limited

Biological E. Limited

Boryung Pharmaceutical Co., Ltd.

Daiichi Sankyo Company, Limited

GlaxoSmithKline Plc

Green Cross Corporation

Indian Immunologicals Limited

LG Life Sciences, Ltd.

Panacea Biotec Limited

Prometheon Pharma, LLC

Sanofi

Sanofi Pasteur SA

Serum Institute of India Limited

Sinovac Biotech Ltd.

Zydus Cadila Healthcare Limited

Tetanus - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(diphtheria + tetanus + pertussis (acellular) + poliovirus) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

(diphtheria + tetanus + pertussis) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

diphtheria + pertussis (acellular) + tetanus vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

diphtheria + pertussis (acellular) + tetanus vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

diphtheria + pertussis + tetanus + hepatitis B + haemophilus influenza [serotype B] vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

diphtheria + tetanus + pertussis (acellular) + haemophilus influenza [serotype B] + polio [sabin] vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

diphtheria + tetanus + pertussis (acellular) + haemophilus influenza [serotype B] vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

diphtheria + tetanus + pertussis (acellular) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

diphtheria + tetanus + pertussis (acellular) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

diphtheria + tetanus + pertussis (acellular) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

diphtheria + tetanus + pertussis (whole cell) + haemophilus influenzae [serotype B] + polio (pentavalent) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [serotype B] + polio (hexavalent) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

diphtheria + tetanus + pertussis (whole-cell) + haemophilus influenzae [serotype B] vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

diphtheria + tetanus + pertussis (whole-cell) + hepatitis B + haemophilus influenzae [serotype B] (pentavalent) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

diphtheria + tetanus + pertussis (whole-cell) + hepatitis B + haemophilus influenzae [serotype B] vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

diphtheria + tetanus + pertussis (whole-cell) + poliomyelitis + haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] (7-valent) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

diphtheria + tetanus + pertussis (whole-cell) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

diphtheria + tetanus vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

diphtheria + tetanus+ pertussis (whole cell) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + haemophilus influenzae [type B] (pentavalent) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + poliomyelitis + haemophilus influenzae [type B] (hexavalent) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

GC-1107 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

GC-3111A - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PR-5I - Drug Profile

Product Description

Mechanism of Action

R&D Progress

tetanus + diphtheria + pertussis (acellular) vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

tetanus vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

tetanus vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

tetanus vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

tetanus vaccine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

VN-0103 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Tetanus - Recent Pipeline Updates

Tetanus - Dormant Projects

Tetanus - Discontinued Products

Tetanus - Product Development Milestones

Featured News & Press Releases

Nov 14, 2014: Biological E To Supply Pentavalent Vaccine For Telangana State Immunization Program

Oct 20, 2014: US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur’s Investigational Pediatric Hexavalent Vaccine

Apr 01, 2014: Sanofi Pasteur Announces FDA Has Expanded Age Indication of Adacel® Tdap Vaccine to Include Persons 10 Years of Age

Jul 25, 2005: Sanofi pasteur Begins Shipping ADACEL Vaccine in the U.S. for Combined Protection against Tetanus, Diphtheria, and Pertussis

Jun 13, 2005: U.S. FDA Licenses sanofi pasteur’s ADACEL Vaccine for Combined Protection Against Tetanus, Diphtheria and Pertussis

Jun 10, 2005: Society for Adolescent Medicine Statement on the FDA Licensure of Adacel Vaccine

Mar 18, 2005: FDA Advisory Panel Recommends Licensure of sanofi pasteur’s ADACEL Vaccine for Combined Protection against Tetanus, Diphtheria and Pertussis

Aug 11, 2004: Aventis Submits Application for FDA Licensure of ADACEL Vaccine for Prevention of Tetanus, Diphtheria and Pertussis in Adolescents and Adults.

Aug 28, 2000: Aventis Pasteur Inc. Gets FDA Approval to Expand Use of Tripedia to Fifth Consecutive Dose in Diphtheria/Tetanus/Pertussis Immunization Series.

Jul 13, 1995: Connaught Laboratories, Inc. Applies to FDA for Licensing of Tripedia for Infant Use

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Tetanus, H2 2015

Number of Products under Development for Tetanus - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Products under Development by Companies, H2 2015

Products under Development by Companies, H2 2015 (Contd..1)

Products under Investigation by Universities/Institutes, H2 2015

Tetanus - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2015

Tetanus - Pipeline by Bharat Biotech International Limited, H2 2015

Tetanus - Pipeline by Biological E. Limited, H2 2015

Tetanus - Pipeline by Boryung Pharmaceutical Co., Ltd., H2 2015

Tetanus - Pipeline by Daiichi Sankyo Company, Limited, H2 2015

Tetanus - Pipeline by GlaxoSmithKline Plc, H2 2015

Tetanus - Pipeline by Green Cross Corporation, H2 2015

Tetanus - Pipeline by Indian Immunologicals Limited, H2 2015

Tetanus - Pipeline by LG Life Sciences, Ltd., H2 2015

Tetanus - Pipeline by Panacea Biotec Limited, H2 2015

Tetanus - Pipeline by Prometheon Pharma, LLC, H2 2015

Tetanus - Pipeline by Sanofi, H2 2015

Tetanus - Pipeline by Sanofi Pasteur SA, H2 2015

Tetanus - Pipeline by Serum Institute of India Limited, H2 2015

Tetanus - Pipeline by Sinovac Biotech Ltd., H2 2015

Tetanus - Pipeline by Zydus Cadila Healthcare Limited, H2 2015

Assessment by Monotherapy Products, H2 2015

Assessment by Combination Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Tetanus Therapeutics - Recent Pipeline Updates, H2 2015

Tetanus - Dormant Projects, H2 2015

Tetanus - Dormant Projects (Contd..1), H2 2015

Tetanus - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for Tetanus, H2 2015

Number of Products under Development for Tetanus - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Products, H2 2015

Assessment by Monotherapy Products, H2 2015

Assessment by Combination Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 4

Beijing Minhai Biotechnology Co., Ltd
Bharat Biotech International Limited
Biological E. Limited
Boryung Pharmaceutical Co., Ltd.
Daiichi Sankyo Company, Limited
GlaxoSmithKline Plc
Green Cross Corporation
Indian Immunologicals Limited
LG Life Sciences, Ltd.
Panacea Biotec Limited
Prometheon Pharma, LLC
Sanofi
Sanofi Pasteur SA
Serum Institute of India Limited
Sinovac Biotech Ltd.
Zydus Cadila Healthcare Limited

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • Maquet Getinge Group
  • Emergent BioSolutions, Inc.
  • Aicuris GmbH & Co.KG
  • Merck & Co., Inc.